First in human study of antiCCL20 monoclonal antibody (GSK3050002)

• Research type

  Research Study

• Full title

  A Phase 1, Randomized, Double-Blind (sponsor open), Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (anti-CCL20 monoclonal antibody) in Healthy Male Volunteers

• IRAS ID

  140129

• Contact name

  Disala Fernando

• Contact email

  disala.x.fernando@gsk.com

• Eudract number

  2013-004050-19

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  13/SC/0584

• Date of REC Opinion

  26 Nov 2013

• REC opinion

  Further Information Favourable Opinion